KT A522
Alternative Names: AAV-GLP1-RA; KT-A522Latest Information Update: 28 Jun 2024
At a glance
- Originator Kriya Therapeutics
- Class Antihyperglycaemics; Gene therapies; Obesity therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Obesity in USA (Parenteral, Injection)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Parenteral, Injection)
- 12 May 2020 Preclinical trials in Obesity in USA (Parenteral)